10,120 Shares in Amphastar Pharmaceuticals Inc (AMPH) Acquired by Municipal Employees Retirement System of Michigan

Municipal Employees Retirement System of Michigan acquired a new position in shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) in the 4th quarter, Holdings Channel reports. The fund acquired 10,120 shares of the company’s stock, valued at approximately $201,000.

Several other large investors also recently modified their holdings of AMPH. Acadian Asset Management LLC purchased a new stake in shares of Amphastar Pharmaceuticals during the 4th quarter worth approximately $63,000. First Quadrant L P CA purchased a new stake in shares of Amphastar Pharmaceuticals during the 4th quarter worth approximately $67,000. LS Investment Advisors LLC lifted its position in shares of Amphastar Pharmaceuticals by 217.9% during the 4th quarter. LS Investment Advisors LLC now owns 3,522 shares of the company’s stock worth $70,000 after buying an additional 2,414 shares during the last quarter. Quantamental Technologies LLC purchased a new stake in shares of Amphastar Pharmaceuticals during the 4th quarter worth approximately $71,000. Finally, Meeder Asset Management Inc. purchased a new stake in shares of Amphastar Pharmaceuticals during the 4th quarter worth approximately $92,000. Institutional investors and hedge funds own 47.57% of the company’s stock.

AMPH stock opened at $20.58 on Wednesday. Amphastar Pharmaceuticals Inc has a 12 month low of $14.40 and a 12 month high of $25.43. The firm has a market capitalization of $973.21 million, a P/E ratio of 90.43, a price-to-earnings-growth ratio of 2.38 and a beta of 1.37. The company has a quick ratio of 1.41, a current ratio of 2.06 and a debt-to-equity ratio of 0.09.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Tuesday, March 12th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.11 by $0.02. Amphastar Pharmaceuticals had a negative net margin of 1.96% and a positive return on equity of 3.17%. The firm had revenue of $89.69 million during the quarter, compared to the consensus estimate of $75.46 million. On average, equities research analysts forecast that Amphastar Pharmaceuticals Inc will post 0.35 earnings per share for the current fiscal year.

Several analysts have recently weighed in on AMPH shares. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 3rd. TheStreet upgraded shares of Amphastar Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Friday, January 11th. BidaskClub downgraded shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 25th. Finally, Piper Jaffray Companies downgraded shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $24.00 to $23.00 in a research report on Wednesday, March 13th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $23.73.

In related news, SVP Yakob Liawatidewi sold 7,000 shares of the company’s stock in a transaction on Wednesday, January 23rd. The shares were sold at an average price of $22.52, for a total value of $157,640.00. Following the completion of the sale, the senior vice president now owns 40,463 shares in the company, valued at approximately $911,226.76. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Jason B. Shandell sold 32,336 shares of the company’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $20.35, for a total transaction of $658,037.60. Following the completion of the sale, the insider now owns 160,490 shares of the company’s stock, valued at approximately $3,265,971.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 113,122 shares of company stock valued at $2,561,811. 31.50% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This story was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.com-unik.info/2019/04/17/10120-shares-in-amphastar-pharmaceuticals-inc-amph-acquired-by-municipal-employees-retirement-system-of-michigan.html.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Read More: Differences Between Momentum Investing and Long Term Investing

Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH).

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit